Bone Remodeling, Bone Mass and Weight Gain in Patients with Stabilized Schizophrenia in Real-Life Conditions Treated with Long-Acting Injectable Risperidone

Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management

(2010) Richard I. G. Holt et al.   CLINICAL ENDOCRINOLOGY

The Central Regulation of Bone Mass, The First Link between Bone Remodeling and Energy Metabolism

(2010) Gerard Karsenty et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia

(2010) Dhiren Singh et al.   Clinical Interventions in Aging

Bone mass in schizophrenia and normal populations across different decades of life

(2009) Jenn-Huei Renn et al.   BMC MUSCULOSKELETAL DISORDERS

A Serotonin-Dependent Mechanism Explains the Leptin Regulation of Bone Mass, Appetite, and Energy Expenditure

(2009) Vijay K. Yadav et al.   CELL

Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets

(2009) Solrun Vidarsdottir et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Antipsychotic-Induced Hyperprolactinemia Inhibits the Hypothalamo-Pituitary-Gonadal Axis and Reduces Bone Mineral Density in Male Patients With Schizophrenia

(2009) Taishiro Kishimoto et al.   JOURNAL OF CLINICAL PSYCHIATRY

Multiple Genetic Factors in Olanzapine-Induced Weight Gain in Schizophrenia Patients

(2009) Hiroshi Ujike et al.   JOURNAL OF CLINICAL PSYCHIATRY

Femoral bone mineral density and bone mineral content in bromocriptine-treated pregnant and lactating rats

(2009) Panan Suntornsaratoon et al.   Journal of Physiological Sciences

Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents

(2009) Sun H. Kim et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications

(2009) S. Gentile   Obesity Reviews

Regulation of bone remodeling by the central and peripheral nervous system

(2008) Florent Elefteriou   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Molecular bases of the sympathetic regulation of bone mass

(2008) Shu Takeda et al.   BONE

Upcoming Agents for the Treatment of Schizophrenia

(2008) Delia Bishara et al.   DRUGS

Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone

(2008) P.-M. Llorca et al.   ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE

Prolactin awareness: An essential consideration for physical health in schizophrenia

(2008) Angel L. Montejo   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia

(2008) Veronica O'Keane   JOURNAL OF PSYCHOPHARMACOLOGY

High bone turnover but normal bone mineral density in women suffering from schizophrenia

(2008) N. Bergemann et al.   PSYCHOLOGICAL MEDICINE

Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor κB ligand/osteoprotegerin ratio

(2007) Dutmanee Seriwatanachai et al.   BONE